You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 13, 2024

~ Buy the YONDELIS (trabectedin) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR YONDELIS


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for YONDELIS

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00060944 ↗ A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Completed PharmaMar Phase 2 2003-05-01 The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
NCT00060944 ↗ A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 2 2003-05-01 The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
NCT00070109 ↗ Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed National Cancer Institute (NCI) Phase 2 2008-01-01 This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00070109 ↗ Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed Children's Oncology Group Phase 2 2008-01-01 This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00072670 ↗ A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer Completed PharmaMar Phase 2 2004-01-01 The purpose of this study is to evaluate safety and efficacy of trabectedin (ET-743) in adult male participants with advanced metastatic (spread of cancer cells from one part of the body to another) prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for YONDELIS

Condition Name

Condition Name for YONDELIS
Intervention Trials
Sarcoma 8
Soft Tissue Sarcoma 8
Leiomyosarcoma 5
Ovarian Cancer 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for YONDELIS
Intervention Trials
Sarcoma 23
Leiomyosarcoma 10
Liposarcoma 9
Ovarian Neoplasms 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for YONDELIS

Trials by Country

Trials by Country for YONDELIS
Location Trials
United States 218
Italy 100
Spain 17
Germany 16
France 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for YONDELIS
Location Trials
California 12
Massachusetts 10
Texas 9
Pennsylvania 9
Ohio 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for YONDELIS

Clinical Trial Phase

Clinical Trial Phase for YONDELIS
Clinical Trial Phase Trials
Phase 3 11
Phase 2 27
Phase 1/Phase 2 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for YONDELIS
Clinical Trial Phase Trials
Completed 31
Recruiting 8
Terminated 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for YONDELIS

Sponsor Name

Sponsor Name for YONDELIS
Sponsor Trials
PharmaMar 18
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 8
National Cancer Institute (NCI) 7
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for YONDELIS
Sponsor Trials
Other 52
Industry 41
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.